Yesterday’s 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Helsinki reported a significant addition to the dwindling number of drugs in the fight against the hospital ‘Superbug’, Methicillin Resistant Staphylococcus aureus (MRSA).

UK-based pharmaceutical company Destiny Pharma presented research into the rapid anti-bacterial activity of its latest platform of drugs against Staphylococcus aureus on the second day of the conference. Whilst the company’s lead anti-microbial XF-73 continues on course within Phase I/IIa clinical development, Destiny has now demonstrated the novel anti-bacterial mechanism of action of DPD-207. This is an example of its new platform of Metallo-Porphyrin (MP) drugs which has been proven to act in a similar manner to the XF drug platform. Read the rest of this entry »